The Clinical Use of Factor IX Concentrates

1975 ◽  
Vol 33 (03) ◽  
pp. 403-404
Author(s):  
Rosemary Biggs
Keyword(s):  
1980 ◽  
Vol 44 (02) ◽  
pp. 081-086 ◽  
Author(s):  
C V Prowse ◽  
A E Williams

SummaryThe thrombogenic effects of selected factor IX concentrates were evaluated in two rabbit models; the Wessler stasis model and a novel non-stasis model. Concentrates active in either the NAPTT or TGt50 in vitro tests of potential thrombogenicity, or both, caused thrombus formation in the Wessler technique and activation of the coagulation system in the non-stasis model. A concentrate with low activity in both in vitro tests did not have thrombogenic effects in vivo, at the chosen dose. Results in the non-stasis model suggested that the thrombogenic effects of factor IX concentrates may occur by at least two mechanisms. A concentrate prepared from platelet-rich plasma and a pyrogenic concentrate were also tested and found to have no thrombogenic effect in vivo.These studies justify the use of the NAPTT and TGt50 in vitro tests for the screening of factor IX concentrates prior to clinical use.


Vox Sanguinis ◽  
1969 ◽  
Vol 16 (5) ◽  
pp. 398-411 ◽  
Author(s):  
C. Haanen ◽  
R. L. McShine ◽  
A. Kunst
Keyword(s):  

1990 ◽  
Vol 20 (5) ◽  
pp. 276-288
Author(s):  
R. Wagenvoord ◽  
H. Hendrix ◽  
T. Tran ◽  
H.C. Hemker
Keyword(s):  

1993 ◽  
Vol 19 (01) ◽  
pp. 25-36 ◽  
Author(s):  
Arthur Thompson
Keyword(s):  

Vox Sanguinis ◽  
1969 ◽  
Vol 16 (4-5) ◽  
pp. 398-411
Author(s):  
C. Haanen ◽  
R.L. McShine ◽  
A. Kunst
Keyword(s):  

Vox Sanguinis ◽  
1973 ◽  
Vol 25 (5) ◽  
pp. 426-441 ◽  
Author(s):  
T. W. Barrowcliffe ◽  
Penelope Stableforth ◽  
Katharine M. Dormandy

Sign in / Sign up

Export Citation Format

Share Document